Q06187 (BTK_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase BTK UniProtKBInterProSTRINGInteractive Modelling

659 aa; Sequence (Fasta) ; (Isoform 2); 10 identical sequences: Pan troglodytes: A0A2I3RVY9; Pan paniscus: A0A2R9BPC2; Gorilla gorilla gorilla: G3SKC9; Mandrillus leucophaeus: A0A2K6A443; Macaca nemestrina: A0A2K6CUV5; Macaca mulatta: F6V0I6, A0A8J8YBS4; Macaca fascicularis: A0A2K5VDZ2; Nomascus leucogenys: G1R7I9; Rhinopithecus roxellana: A0A2K6PTH4

Available Structures

133 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihyd… Heteromer
385-658
100N42;
Structure of cIAP1, BTK and BCCov Heteromer
Q13490;
392-659
100.0TOO;ZN;
Ternary complex structure - BTK cIAP compound 15 Heteromer
Q13490;
393-657
100.0ZN;TKY;
Ternary complex structure - BTK cIAP compound 17 Heteromer
Q13490;
396-656
100TL7;ZN;
Crystal structure of human Btk SH2 domain bound to rF10 repebody Heteromer
276-379
100
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4homo-4-mer2-170
99.4ZN;4IP;
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATEhomo-4-mer2-170
100.0ZN;4IP;
The Crystal Structure of BTK from Biortushomo-2-mer394-658
100.0PEG;EDO;CL;
The structure of human BTK kinase domain in complex with a covalent inhibitorhomo-2-mer394-656
100.0GYL;
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO …homo-2-mer396-656
100.06MV;
Crystal structure of Bruton's tyrosine kinase domainhomo-2-mer397-654
100
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28Chomo-2-mer2-170
99.38ZN;NA;
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGANDmonomer389-659
100GJD;
BTK1 SOAKED WITH IBRUTINIB-Revmonomer389-659
1001E8;DMS;
CRYSTAL STRUCTURE OF BTK with CNX 774monomer389-659
1007G8;
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer389-659
100GJG;
Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-…monomer389-659
10083P;EDO;PEG;
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer389-659
100X9M;
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxy…monomer389-659
100KLM;EDO;
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinibmonomer389-659
100CL;MZJ;
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059monomer389-659
1007GB;DMS;
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer389-659
100GJ7;DMS;
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer389-659
100.04US;DMS;EDO;
Bruton's tyrosine kinase (BTK) with GDC-0853monomer389-659
1009AJ;EDO;SO4;
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinasemonomer389-659
100IMD;IPA;EDO;4L6;
BTK1 SOAKED WITH COMPOUND 25monomer389-659
100X9V;DMS;
BTK in complex with 18Amonomer389-659
1002IE;
Discovery of affinity-based probes for Btk occupancy assaymonomer389-659
100KHD;
Crystal structure of ARQ 531 in complex with the kinase domain of BTKmonomer389-658
100HRA;IMD;EDO;
Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTKmonomer389-658
100.0R1L;DMS;PEG;EDO;SO4;ACT;
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
100IMD;PGO;0BQ;EDO;
BTK1 SOAKED WITH COMPOUND 30monomer390-659
100DMS;X9Y;
BTK in complex with 25Amonomer390-659
100.02IJ;DMS;
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
100IMD;EDO;DMS;0UW;
Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-m…monomer389-658
100WKC;EDO;PD;CL;
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
100.0IMD;PGO;DMS;0GW;
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragmentmonomer389-658
100IMD;IPA;DMS;4RU;
Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitormonomer389-658
100IMD;0CI;DMS;
Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyra…monomer389-658
100YXJ;EDO;CL;
Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[…monomer389-658
100UP9;EDO;CL;IOD;
Bruton's tyrosine kinase (BTK) with compound 13monomer389-658
100UB6;PGE;
Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[…monomer389-658
100UQX;NA;CL;SO4;EDO;
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnolinemonomer389-658
100IMD;IPA;DMS;4RV;
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(…monomer391-659
100.004K;
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(…monomer391-659
100.004L;
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-…monomer391-659
100.0LHL;
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-met…monomer391-659
100.003C;
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer392-659
100.0GJJ;DMS;
BTK In Complex With Inhibitormonomer391-658
100.0LTJ;
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-…monomer391-658
100027;
BTK-inhibitor co-structuremonomer392-659
100.05WH;5WE;
Co-structure of BTK kinase domain with L-005085737 inhibitormonomer392-659
100.0ULV;5WE;
Crystal structure of the covalently bonded complex of rilzabrutinib with BTKmonomer392-659
100R1L;SO4;
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitormonomer391-658
1004C9;NA;EDO;SO4;CL;
BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazo…monomer392-659
100.0KLP;SO4;
Crystal structure of BTK kinase domain complexed with R406monomer391-658
100.0585;
Co-crystal structure of BTK kinase domain with Zanubrutinibmonomer393-659
100BA0;IMD;
Bruton's tyrosine kinase in complex with compound 34monomer393-659
100ZB9;DMS;PEG;
Bruton's tyrosine kinase in complex with compound 5monomer392-658
100.0DMS;RQS;
Bruton's tyrosine kinase in complex with compound 45monomer392-658
100.00B9;
Bruton's tyrosine kinase in complex with compound 6monomer393-659
100DMS;DTT;S5M;
Bruton's tyrosine kinase in complex with an orthosteric inhibitormonomer392-658
100.0DMS;Y8H;
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containi…monomer392-658
100.0B43;
Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phen…monomer392-658
99.61YXJ;EDO;
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer392-658
100X9J;DMS;
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechan…monomer392-658
100.01N1;
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer393-659
100.0GJA;
BTK1 COCRYSTALLIZED WITH IBRUTINIBmonomer394-659
100.08E8;
BTK1 IN COMPLEX WITH CC 292monomer392-657
100.07G9;
Co-structure of BTK kinase domain with L-005298385 inhibitormonomer394-659
100UM4;EDO;BTB;
BTK1 SOAKED WITH COMPOUND 26monomer394-659
100X9P;DMS;
Bruton's tyrosine kinase in complex with compound 1monomer393-658
100.0S9A;DMS;
Bruton's tyrosine kinase in complex with covalent inhibitor compound 25monomer394-659
100.0V72;
Bruton's tyrosine kinase in complex with compound 21monomer393-658
100.00BG;DMS;
Bruton's tyrosine kinase in complex with compound 23monomer393-658
100.0YD7;DMS;
Bruton's tyrosine kinase in complex with covalent inhibitor compound 10monomer394-659
100.0UEO;
BTK IN COMPLEX WITH GDC-0834monomer394-659
1002VL;EDO;GOL;
BTK in complex with LOU064, a potent and highly selective covalent inhibitormonomer393-658
100NA;N6Z;
BTK complex with compound 12monomer393-657
100SO4;DXM;FPZ;GOL;
Bruton's tyrosine kinase in complex with compound 51monomer394-658
100YDA;DTT;ACT;
Brutons tyrosine kinase in complex with compound 50.monomer395-659
100.0L9S;EDO;
Structure of BTK with RN486monomer394-658
1007G6;
Co-structure of BTK kinase domain with L-005191930 inhibitormonomer395-659
100ULY;5WE;
BTK1 SOAKED WITH COMPOUND 24monomer395-659
100X9S;DMS;
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-ca…monomer394-658
98.492V1;
Bruton's tyrosine kinase in complex with compound 65monomer394-658
100.00B0;
Bruton's tyrosine kinase in complex with an orthosteric inhibitormonomer395-659
100.0DMS;Y8C;
Crystal structure of the human BTK kinase domainmonomer394-658
100.0
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23monomer394-657
100SO4;GOL;PG0;3YO;
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9monomer394-657
100SO4;GOL;PG0;6XL;
Co-crystal structure of BTK kinase domain with inhibitormonomer395-658
100IS4;EDO;
Crystal structure of BTK kinase domain in complex with pirtobrutinibmonomer395-658
100Y7W;SO4;GOL;BTB;
Bruton's tyrosine kinase (BTK) with compound G-744monomer394-657
100SO4;GOL;PG0;9B1;
BTK kinase domain with inhibitor 1monomer395-658
100.05WF;5WE;CL;
BTK1 COCRYSTALLIZED WITH RN983monomer395-658
1007G7;
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer396-658
98.48GMQ;
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethy…monomer396-658
98.483OV;DMS;
BTK complex with compound 13monomer395-657
100SO4;DY4;GOL;
Crystal structure of BTK C481S kinase domain in complex with pirtobrutinibmonomer395-657
99.62Y7W;SO4;GOL;BTB;
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-…monomer396-658
98.48GMW;
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fl…monomer396-658
100.073T;
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-…monomer396-658
98.482V2;DMS;
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-…monomer396-658
98.48481;DMS;
BTK Fluorocyclopropyl amide inhibitor, Compound 25monomer395-657
100V1G;SO4;
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815monomer395-657
100SO4;BXM;
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625monomer394-656
99.62GOL;SO4;BXJ;
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer396-658
98.483OU;DMS;
BTK complex with compound 7monomer395-657
100SO4;DTJ;GOL;
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1…monomer396-658
98.482V3;DMS;
BTK complex with compound 10monomer395-657
100SO4;DVJ;
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinibmonomer394-656
100.01N1;
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperaz…monomer396-658
98.48BNB;
Bruton's tyrosine kinase in complex with covalent inhibitor compound 27monomer395-657
100.0V7I;
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-…monomer396-658
98.483P0;
BTK complex with compound 11monomer396-657
100SO4;DVD;
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746monomer395-656
100SO4;BME;746;
BTK in complex with an inhibitormonomer395-656
100L0Z;
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834monomer396-657
100SO4;2VL;
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert…monomer396-657
100.02P5;
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer396-657
1004UQ;
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2emonomer395-655
1009M3;
The PH domain of Bruton's tyrosine kinase mutant R28Cmonomer2-169
99.39MG;ZN;
Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer2-169
99.39MG;72V;ZN;
Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer2-169
99.363IS;ZN;MG;
Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Br…monomer2-169
100.0Q1B;MG;ZN;
Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's t…monomer2-169
99.39ZN;MG;
PH domain of Bruton's tyrosine kinase bound to compound 1monomer2-168
99.36NXT;MG;ZN;
Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosi…monomer2-168
99.38NYQ;ZN;MG;
Crystal structure of PH domain of Bruton's tyrosine kinasemonomer2-168
100.0ZN;4PT;
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinasemonomer270-387
100
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURESmonomer211-275
98.46
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTUREmonomer211-275
98.46
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structuresmonomer216-273
100

7 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8gmb.1.Amonomer0.74214-659
95.90
1qcf.1.Amonomer0.71217-656
38.66
1y57.1.Amonomer0.69216-656
38.62
1opl.2.Amonomer0.69275-657
39.82
1k9a.1.Amonomer0.68214-657
37.30
4y93.1.Amonomer0.611-658
ZN;95.96
8s93.1.Amonomer0.591-659
ZN;92.34

6 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 28gmb.1.Amonomer0.73248-693
95.90
Isoform 28jn8.1.Amonomer0.69250-691
38.18
Isoform 21y57.1.Amonomer0.69250-690
38.62
Isoform 21opl.2.Amonomer0.69309-691
39.82
Isoform 24y93.1.Amonomer0.6135-692
ZN;96.40
Isoform 28s93.1.Amonomer0.5835-693
ZN;92.56